NSCLC - Non Small Cell Lung Cancer Now Closed
CCTG BR.31 - Hosted By elie
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
| Study Type | Treatment |
| Sponsor Name | Astrazeneca |
| Disease type | Non-Small Cell Lung Cancer |
| Disease Stage | IB – IIIA |
| Clinical Status | Adjuvant |
| Phase | III |
| Intervention / Treatment | Durvalumab versus Placebo |
| Research Site | Quebec Heart and Lung Institute |
| Investigator | Dre Lise Tremblay |
| Coordinator | Brigitte Fortin |
| Telephone number | |
| Fax number | |
| Study start date | October 9, 2014 |
| Study end date | |
| Trial Status | Recruiting |
| Study Type | Treatment, Interventional |
| Sponsor Name | |
| Tumor Site | NSCLC - Non Small Cell Lung Cancer |
| Disease Stage | Stage I, Stage II, Stage III |
| Clinical Status | Adjuvant, Operable |
| Phase | Phase I |
| Intervention / Treatment | |
| Research Site | Quebec, Quebec Heart and Lung Institute |
| Investigator | |
| Coordinator | |
| Telephone Number | +1 418 656-8711 |
| Fax Number | |
| Study Start Date | |
| Study End Date | |
| Trial Status |
